Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 46:1425-1433, doi:10.1016/j.jacc.2005.05.086
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (49)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ray, K. K.
Right arrow Articles by Cannon, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ray, K. K.
Right arrow Articles by Cannon, C. P.

FOCUS ISSUE: PROVE IT-TIMI 22: STATE-OF-THE-ART PAPER

The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes

Kausik K. Ray, MRCP, MD* and Christopher P. Cannon, MD, FACC

Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts

Manuscript received March 18, 2005; revised manuscript received May 12, 2005, accepted May 16, 2005.

* Reprint requests and correspondence: Dr. Kausik K. Ray, The TIMI Study Group, 350 Longwood Avenue, 1st Floor, Boston Massachusetts 02115 (Email: kkray{at}partners.org).

Emerging data suggest that acute presentations of coronary artery disease may involve a complex interplay between the vessel wall, inflammatory cells, and the coagulation cascade. Although a culprit thrombotic lesion may be treated effectively by antithrombotic therapy and revascularization, this will have little effect on the global processes that determine recurrent events at non-culprit sites. Thus, additional systemic treatment is required to modulate the adverse biological features that are the hallmark of acute coronary syndromes (ACS). Statins possess multiple beneficial effects that are independent of low-density-lipoprotein cholesterol (LDL-C) lowering and that have favorable effects on inflammation, the endothelium, and the coagulation cascade. In the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial, differences were seen based on achieved LDL-C that could be further discriminated by the achieved C-reactive protein level. Studies of non-vascular disease such as multiple sclerosis have shown that statins reduce inflammation, supporting the presence of lipid-independent effects of statins. This review focuses on the potential importance of these effects in the management of ACS.

Abbreviations and Acronyms
  ACS = acute coronary syndromes
  CAD = coronary artery disease
  CRP = C-reactive protein
  HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
  ICAM = intercellular adhesion molecule
  IL = interleukin
  LDL-C = low-density lipoprotein cholesterol
  NO = nitric oxide
  PAI-1 = plasminogen activator inhibitor
  PROVE IT-TIMI 22 = Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22
  TF = tissue factor
  TM = thrombomodulin
  tPA = tissue plasminogen activator
  vWF = von Willebrand factor




This article has been cited by other articles:


Home page
AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
A. S. Leon and U. G. Bronas
Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management
American Journal of Lifestyle Medicine, July 1, 2009; 3(4): 257 - 273.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
H. Yasue, Y. Mizuno, E. Harada, T. Itoh, H. Nakagawa, M. Nakayama, H. Ogawa, S. Tayama, T. Honda, S. Hokimoto, et al.
Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers
J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1742 - 1748.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Desjardins, B. Sekkali, W. Verreth, M. Pelat, D. De Keyzer, A. Mertens, G. Smith, M.-C. Herregods, P. Holvoet, and J.-L. Balligand
Rosuvastatin increases vascular endothelial PPAR{gamma} expression and corrects blood pressure variability in obese dyslipidaemic mice
Eur. Heart J., January 1, 2008; 29(1): 128 - 137.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
R. R. S. Packard, S. Schlegel, D. Senouf, F. Burger, P. Sigaud, T. Perneger, C.-A. Siegrist, and F. Mach
Atorvastatin Treatment and Vaccination Efficacy
J. Clin. Pharmacol., August 1, 2007; 47(8): 1022 - 1027.
[Full Text] [PDF]


Home page
Anesth. Analg.Home page
Y. Le Manach, G. Godet, P. Coriat, C. Martinon, M. Bertrand, M.-H. Fleron, and B. Riou
The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery
Anesth. Analg., June 1, 2007; 104(6): 1326 - 1333.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. P. Alexander, L. K. Newby, P. W. Armstrong, C. P. Cannon, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al.
Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Circulation, May 15, 2007; 115(19): 2570 - 2589.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. J. Nicholls, E. M. Tuzcu, I. Sipahi, A. W. Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Y. Desai, S. L. Hazen, et al.
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
JAMA, February 7, 2007; 297(5): 499 - 508.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
O. A. Iakoubova, C. H. Tong, A. P. Chokkalingam, C. M. Rowland, T. G. Kirchgessner, J. Z. Louie, L. M. Ploughman, M. S. Sabatine, H. Campos, J. J. Catanese, et al.
Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS
Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2763 - 2768.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. T. Kinobe, R. A. Dercho, J. Z. Vlahakis, J. F. Brien, W. A. Szarek, and K. Nakatsu
Inhibition of the Enzymatic Activity of Heme Oxygenases by Azole-Based Antifungal Drugs
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 277 - 284.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
K. B. Keller and L. Lemberg
Secondary prevention of coronary artery disease in elderly persons: a treatise on a report by the american heart association.
Am. J. Crit. Care., September 1, 2006; 15(5): 514 - 518.
[Full Text] [PDF]


Home page
CirculationHome page
D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. D. Wiviott, M. A. Blazing, A. Shui, N. Rifai, R. M. Califf, and E. Braunwald
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
Circulation, July 25, 2006; 114(4): 281 - 288.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement